Patents Assigned to Signal Pharmaceuticals, Inc.
-
Patent number: 7202049Abstract: Compositions and methods are provided for the treatment of diseases associated with mitogen activated protein kinase cascades. In particular, the mitogen-activated protein kinase p38-2, and polypeptide variants thereof that stimulate phosphorylation and activation of substrates such as ATF2, are provided. The polypeptides may be used, for example, to identify antibodies and other agents that inhibit or activate signal transduction via the p38-2 kinase cascade. Such polypeptides and agents may also be used for the treatment of diseases associated with mitogen-activated protein kinase cascades.Type: GrantFiled: July 16, 2002Date of Patent: April 10, 2007Assignee: Signal Pharmaceuticals, Inc.Inventors: Bernd Stein, Maria X. H. Yang, David B. Young
-
Patent number: 6897231Abstract: Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.Type: GrantFiled: July 23, 2001Date of Patent: May 24, 2005Assignee: Signal Pharmaceuticals, Inc.Inventors: Shripad S. Bhagwat, Yoshitaka Satoh, Steven T. Sakata, Chris A. Buhr, Ronald Albers, John Sapienza, Veronique Plantevin, Qi Chao, Kiran Sahasrabudhe, Rachel Ferri
-
Patent number: 6835567Abstract: Conditionally-immortalized PNS progenitor cell lines are provided. Such cell lines, which may be clonal, may be used to generate neurons. The cell lines and/or differentiated cells may be used for the development of therapeutic agents to prevent and treat a variety of PNS-related diseases. The cell lines and/or differentiated cells may also be used in assays and for the general study of PNS cell development, death and abnormalities.Type: GrantFiled: April 14, 1998Date of Patent: December 28, 2004Assignee: Signal Pharmaceuticals, Inc.Inventors: Dinah W. Y. Sah, Heather K. Raymon
-
Publication number: 20040235112Abstract: Compositions and methods are provided for potentiating the activity of the mitogen-activated protein kinase p38. In particular the mitogen-activated protein kinase kinase MEK6, and variants thereof that stimulate phosphorylation of p38 are provided. Such compounds may be used, for example, for therapy of diseases associated with the p38 cascade and to identify antibodies and other agents that inhibit or activate signal transduction via p38.Type: ApplicationFiled: June 16, 2004Publication date: November 25, 2004Applicant: Signal Pharmaceuticals, Inc.Inventors: Bernd Stein, Maria X. H. Yang
-
Publication number: 20040082575Abstract: Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-&bgr; over ER-&agr;. Methods are disclosed for modulating ER-&bgr; in cell and/or tissues expressing the same, including cells and/or tissue that preferentially ER-&bgr;. Methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natureal hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.Type: ApplicationFiled: May 7, 2003Publication date: April 29, 2004Applicant: Signal Pharmaceuticals, Inc.Inventors: Shripad S. Bhagwat, Leah Marie Gayo-Fung, Bernd M. Stein, Qi Chao, Anthony R. Gangloff, Jeffrey A. McKie, Kenneth D. Rice
-
Publication number: 20040077877Abstract: Compounds having activity as selective inhibitors of JNK are disclosed.Type: ApplicationFiled: September 26, 2003Publication date: April 22, 2004Applicant: Signal Pharmaceuticals, Inc.Inventors: Shripad S. Bhagwat, Yoshitaka Satoh, Steven T. Sakata, Chris A. Buhr, Ronald Albers, John Sapienza, Veronique Plantevin, Qi Chao, Kiran Sahasrabudhe, Rachel Ferri
-
Patent number: 6686351Abstract: Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-&bgr; over ER-&agr;. Methods are disclosed for modulating ER-&bgr; in cell and/or tissues expressing the same, including cells and/or tissue that preferentially express ER-&bgr;. More generally, methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natural hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.Type: GrantFiled: February 27, 2002Date of Patent: February 3, 2004Assignee: Signal Pharmaceuticals, Inc.Inventors: Shripad S. Bhagwat, Leah M. Gayo-Fung, Qi Chao
-
Patent number: 6677130Abstract: Compositions and methods are provided for the treatment of diseases associated with mitogen activated protein kinase cascades. In particular, the mitogen-activated protein kinase p38-2, and polypeptide variants thereof that stimulate phosphorylation and activation of substrates such as ATF2, are provided. The polypeptides may be used, for example, to identify antibodies and other agents that inhibit or activate signal transduction via the p38-2 kinase cascade. Such polypeptides and agents may also be used for the treatment of diseases associated with mitogen-activated protein kinase cascades.Type: GrantFiled: November 28, 2000Date of Patent: January 13, 2004Assignee: Signal Pharmaceuticals, Inc.Inventors: Bernd Stein, Maria X. H. Yang, David B. Young
-
Patent number: 6656713Abstract: Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.Type: GrantFiled: April 9, 2001Date of Patent: December 2, 2003Assignee: Signal Pharmaceuticals, Inc.Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
-
Publication number: 20030175928Abstract: Compositions and methods are provided for potentiating the activity of the mitogen-activated protein kinase p38. In particular the mitogen-activated protein kinase kinase MEK6, and variants thereof that stimulate phosphorylation of p38 are provided. Such compounds may be used, for example, for therapy of diseases associated with the p38 cascade and to identify antibodies and other agents that inhibit or activate signal transduction via p38.Type: ApplicationFiled: April 2, 2003Publication date: September 18, 2003Applicant: Signal Pharmaceuticals, Inc.Inventors: Bernd Stein, Maria X. H. Yang
-
Patent number: 6620838Abstract: Benzopyranone compounds having the following structure: wherein R1, X, Y and n are as defined here, are disclosed. The compounds of formula (I), wherein R1 is H, can be prepared by demethylation of the corresponding phenolic methyl ether. The compounds are useful for treating a bone-resorbing disease, cancer, arthritis or an estrogen-related condition such as breast cancer, osteoporosis and endometriosis.Type: GrantFiled: April 19, 2002Date of Patent: September 16, 2003Assignee: Signal Pharmaceuticals, Inc.Inventors: Jeffrey A. McKie, Shripad S. Bhagwat, Johanne Renaud, Martin Missbach
-
Publication number: 20030149025Abstract: This invention relates to methods for using benzopyranones, or their pharaceutically acceptable salts, for treating or preventing a primary brain cancer or a brain metastasis.Type: ApplicationFiled: September 30, 2002Publication date: August 7, 2003Applicant: Signal Pharmaceuticals, Inc.Inventor: Jerome B. Zeldis
-
Patent number: 6593322Abstract: Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-&bgr; over ER-&agr;. Methods are disclosed for modulating ER-&bgr; in cell and/or tissues expressing the same, including cells and/or tissue that preferentially ER-&bgr;. Methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natureal hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.Type: GrantFiled: September 21, 2000Date of Patent: July 15, 2003Assignee: Signal Pharmaceuticals, Inc.Inventors: Shripad S. Bhagwat, Leah Marie Gayo-Fung, Bernd M. Stein, Qi Chao, Anthony R. Gangloff, Jeffrey A. McKie, Kenneth D. Rice
-
Publication number: 20030119072Abstract: Methods are provided for identifying agents that modulate signaling mediated by transforming growth factor beta (TGF-&bgr;) and members of the TGF-&bgr; family, such as bone morphogenic protein (BMP). Such agents may be identified using screens that evaluate candidate agents for the ability to modulate Smad protein degradation. Agents identified as described herein may be used to augment or inhibit signaling mediated by one or more TGF-&bgr; family members in a variety of cell types and for therapeutic purposes.Type: ApplicationFiled: December 2, 2002Publication date: June 26, 2003Applicant: Signal Pharmaceuticals, Inc.Inventors: Merl F. Hoekstra, Weilin Xie, Brion W. Murray, Frank M. Mercurio
-
Patent number: 6576437Abstract: Compositions and methods are provided for treating NF-&kgr;B-related conditions. In particular, the invention provides a stimulus-inducible IKK signalsome, and components and variants thereof. An IKK signalsome or component thereof may be used, for example, to identify antibodies and other modulating agents that inhibit or activate signal transduction via the NF-&kgr;B cascade. IKK signalsome, components thereof and/or modulating agents may also be used for the treatment of diseases associated with NF-&kgr;B activation.Type: GrantFiled: April 27, 2001Date of Patent: June 10, 2003Assignee: Signal Pharmaceuticals, Inc.Inventors: Frank Mercurio, Hengyi Zhu, Miguel Barbosa, Jian Wu Li, Brion W. Murray
-
Publication number: 20030087901Abstract: Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-&bgr; over ER-&agr;. Methods are disclosed for modulating ER-&bgr; in cell and/or tissues expressing the same, including cells and/or tissue that preferentially express ER-&bgr;. More generally, methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natural hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.Type: ApplicationFiled: February 27, 2002Publication date: May 8, 2003Applicant: Signal Pharmaceuticals, Inc.Inventors: Shripad S. Bhagwat, Leah M. Gayo-Fung, Qi Chao
-
Publication number: 20030073732Abstract: Isothiazoloanthrones, isooxazoloanthrones, isoindolanthrones, and derivatives thereof having the general formula: 1Type: ApplicationFiled: February 7, 2002Publication date: April 17, 2003Applicant: Signal Pharmaceuticals, Inc.Inventors: Steven T. Sakata, Heather K. Raymon
-
Publication number: 20030059881Abstract: Compositions and methods are provided for the treatment of diseases associated with mitogen activated protein kinase cascades. In particular, the mitogen-activated protein kinase p38-2, and polypeptide variants thereof that stimulate phosphorylation and activation of substrates such as ATF2, are provided. The polypeptides may be used, for example, to identify antibodies and other agents that inhibit or activate signal transduction via the p38-2 kinase cascade. Such polypeptides and agents may also be used for the treatment of diseases associated with mitogen-activated protein kinase cascades.Type: ApplicationFiled: July 16, 2002Publication date: March 27, 2003Applicant: Signal Pharmaceuticals, Inc.Inventors: Bernd Stein, Maria X.H. Yang, David B. Young
-
Publication number: 20030054528Abstract: Compositions and methods are provided for the treatment of diseases associated with mitogen activated protein kinase cascades. In particular, the mitogen-activated protein kinase p38-2, and polypeptide variants thereof that stimulate phosphorylation and activation of substrates such as ATF2, are provided. The polypeptides may be used, for example, to identify antibodies and other agents that inhibit or activate signal transduction via the p38-2 kinase cascade. Such polypeptides and agents may also be used for the treatment of diseases associated with mitogen-activated protein kinase cascades.Type: ApplicationFiled: July 18, 2002Publication date: March 20, 2003Applicant: Signal Pharmaceuticals, Inc.Inventors: Bernd Stein, Maria X. H. Yang, David B. Young
-
Patent number: 6521601Abstract: A method and pharmaceutical composition for inhibiting viral replication in infected cells are described. The pharmaceutical composition includes a DNA fragment which has covalently linked strands. The DNA fragment contains a 6-30 basepair region whose sequence corresponds to that of a regulatory element in a virus. The method includes introducing a fragment into the cell in an amount sufficient to inhibit replication of the virus in the cell.Type: GrantFiled: April 14, 1992Date of Patent: February 18, 2003Assignee: Signal Pharmaceuticals, Inc.Inventor: Mark D. Carman